Research Analysts Set Expectations for Vyome FY2026 Earnings

Vyome Holdings, Inc. (NASDAQ:HIND) – Litchfield Hills Research increased their FY2026 earnings estimates for Vyome in a report issued on Tuesday, September 22nd. Litchfield Hills Research analyst T. O’neill now forecasts that the company will post earnings of ($0.52) per share for the year, up from their previous estimate of ($0.60).

A number of other brokerages have also weighed in on HIND. Chardan Capital initiated coverage on Vyome in a research report on Thursday, September 3rd. They set a “buy” rating and a $3.50 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Vyome in a research note on Wednesday, July 29th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $9.25.

Vyome Stock Up 3.1%

Shares of HIND stock opened at $2.01 on Thursday. The company’s fifty day simple moving average is $2.14 and its two-hundred day simple moving average is $2.18. Vyome has a 52 week low of $1.75 and a 52 week high of $6.56. The stock has a market cap of $14.11 million, a P/E ratio of -0.60 and a beta of 1.50.

Vyome (NASDAQ:HIND) last posted its earnings results on Wednesday, August 12th. The company reported ($0.10) earnings per share for the quarter. The company had revenue of $0.27 million for the quarter. Vyome had a negative net margin of 3,024.84% and a negative return on equity of 197.33%.

Vyome Company Profile

Vyome Holdings, Inc is a biotechnology company focused on developing therapies for dermatological conditions. The company’s research programs target inflammatory and infectious skin diseases, including acne and other conditions associated with imbalanced skin microbiomes.

Vyome has developed topical drug candidates and proprietary approaches intended to selectively address disease-causing bacteria while preserving beneficial microorganisms on the skin. Its pipeline has included investigational treatments for acne and other dermatology indications, although product candidates remain subject to clinical development and regulatory review.

The company’s operations are centered on the development of prescription dermatology medicines for potential commercialization in the United States and other international markets.